Genetic, Microenvironmental, and Immunological Factors in Unresectable Pancreatic Ductal Adenocarcinoma

  • End date
    Jul 10, 2026
  • participants needed
  • sponsor
    Catholic University of the Sacred Heart
Updated on 26 April 2022
endoscopic ultrasound
cancer chemotherapy
pancreatic ductal adenocarcinoma
breast ductal carcinoma
fine needle biopsy


Pancreatic ductal adenocarcinoma (PDAC) complexity, where genetic, stromal, and immunological factors all interact with each other, is responsible for the overall poor response of PDAC to chemotherapeutic agents, making this a lethal disease. The investigators hypothesize that: (i) dissection of genetic, stromal, and immunological factors on endoscopic ultrasound fine needle biopsy (EUS-FNB) tissue samples from unresectable PDAC patients' will allow to determine prognostic factors in this patient population; (ii) treatment response and acquisition of tumor chemotherapy resistance could be related to genetic heterogeneity between the primary and metastatic sites and alteration of the molecular profile under drug' selection pressure.

Condition Pancreas Cancer
Clinical Study IdentifierNCT05248750
SponsorCatholic University of the Sacred Heart
Last Modified on26 April 2022


Yes No Not Sure

Inclusion Criteria

Patients referred to EUS with FNB for suspected pancreatic cancer unresectable or metastatic based on imaging findings
Availability of biopsies obtained during EUS-FNB
Histological diagnosis of pancreatic ductal adenocarcinoma of any stage
Patients must be fit for chemotherapy administration
They have to express their willingness to be followed up at our pancreatic high volume centers
Age >18 and <80 years
Able to sign informed consent

Exclusion Criteria

Histological diagnoses other than pancreatic ductal adenocarcinoma
Pregnancy or lactation
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note